-
Signature
-
/s/ David E. Jorden, attorney-in-fact
-
Stock symbol
-
AURX
-
Transactions as of
-
Jan 1, 2022
-
Transactions value $
-
$0
-
Form type
-
3/A - Amendment
-
Date filed
-
10/18/2022, 01:20 PM
-
Date Of Original Report
-
Apr 26, 2022
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| holding |
AURX |
Common Stock |
|
|
|
|
|
501K |
Jan 1, 2022 |
Direct |
|
| holding |
AURX |
Common Stock |
|
|
|
|
|
3.47K |
Jan 1, 2022 |
By spouse |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| holding |
AURX |
Option to Purchase Common Stock |
|
|
|
|
|
|
Jan 1, 2022 |
Common Stock |
184K |
$0.40 |
Direct |
|
| holding |
AURX |
Option to Purchase Common Stock |
|
|
|
|
|
|
Jan 1, 2022 |
Common Stock |
81.3K |
$0.40 |
Direct |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Remarks:
(1) Dr. Clausen served as our Chief Scientific Officer until December 31, 2019 and was reappointed as our Chief Scientific Officer as well as our Chief Operating Officer effective January 1, 2022 (2) This amendment corrects an inadvertent error in the amount of indirect shares owned in Table 1. This amendment also adds Table II securities that were inadvertently omitted from the Form 3 as originally filed.